Scientists Race To Develop Next Generation Of COVID Vaccines
The three vaccines available in the U.S. are safe and effective, but not ideal. Now, work is underway to create more convenient and potent vaccines, including a tablet and nasal spray.
ARI SHAPIRO, HOST:
There are now three COVID-19 vaccines available in the United States. And while they are all effective, scientists are already working on the next generation of vaccines to fight the coronavirus, which they hope will be even better. NPR's Joe Palca has this survey of what's on the horizon.
JOE PALCA, BYLINE: The vaccines currently available in this country are safe and effective, but vaccine developer Deborah Fuller at the University of Washington says the ideal vaccine has some other properties
DEBORAH FULLER: Administered in a single shot - right? - be room temperature stable and work in all demographics. And even push beyond that - ideally be self-administered.
PALCA: And vaccines with those characteristics are now making their way through the development pipeline. Take self-administered. Sean Tucker is chief scientific officer at Vaxart.
SEAN TUCKER: We want to develop a platform technology where we could easily give a vaccine and obviously the easiest format to give would be a tablet.
PALCA: The Vaxart COVID tablet vaccine has begun testing in humans. Another vaccine that could be self-administered is a nasal spray. Frances Lund at the University of Alabama, Birmingham is working on one with the biotech company Altimmune. She says when you give people a vaccine by injection, the protection is systemic. That is, it works throughout the body.
FRANCES LUND: By contrast, if you give the vaccine intranasal, you induce two kinds of immunity.
PALCA: You still get the systemic protection.
LUND: But you will also get immunity directly at the site where you put that vaccine.
PALCA: Making it harder for the coronavirus to sneak in through your nose. In addition to new ways to administer COVID vaccines, there are also changes on the horizon for something called the spike protein, the protein that prompts the immune response to the coronavirus. Molecular biologist Jason McLellan at the University of Texas at Austin found that a synthetic form of the spike made a more potent vaccine if you swapped in two amino acids called proline. Now he's made a version with six prolines swapped in.
JASON MCLELLAN: That is a much-improved spike compared to the two-proline version. The protein is much more stable.
PALCA: Another improvement on the horizon is the way the spike protein is packaged for delivery in a vaccine. Jeff Baxter is CEO of VBI Vaccines. He says his company is making a vaccine that's a better mimic of the real coronavirus.
JEFF BAXTER: The size of these particles is perfect for fooling the immune system.
PALCA: Fooling it into thinking it's seeing the real virus when it's just seen a harmless mimic. That's the whole trick behind vaccines. Get the body's immune system ready if the real thing ever comes along. Another kind of approach to making something that looks like a virus but really isn't is to grow the virus-like particles in plants. Turns out you can give plants the genetic instructions for making proteins in the coronavirus, and they'll churn out the vaccine. Brian Ward is medical officer at Medicago, one of the companies trying this approach. He says it's an unusual and positive thing to have so many different kinds of vaccines against a single disease.
BRIAN WARD: That gives us an opportunity to do some things that we've really never done before.
PALCA: Starting with one kind of vaccine and then switching to another may give better immunity than a single vaccine could do on its own. In the end, probably the most important quality a new vaccine must have is the ability to make it and modify it quickly in response to new variants and distribute it rapidly. Nicole Lurie is strategic advisor at CEPI, the Coalition for Epidemic Preparedness Innovations. Some of these new vaccines under development could be available within the year, but Lurie says that's not good enough.
NICOLE LURIE: The year is way too long. And so the aspiration right now is really to think about, OK, what do we need to do to do this in 100 days?
PALCA: Lurie says it's virtually certain the world will face other new and dangerous microbes that will need a vaccine that is...
LURIE: Safe and effective, fast, easy to use, preferably single dose so that when the next one comes, we're much closer to the starting gate than we even were for this one.
PALCA: And she cautions that to do that, scientific advances are needed, but so are regulatory and social changes and maybe a bit more humility and understanding that a microbe can indeed bring the world to its knees.
Joe Palca, NPR News. Transcript provided by NPR, Copyright NPR.
An earlier version of this story misstated the name of the Coalition for Epidemic Preparedness Innovations as the Coalition for Strategic Preparedness and Innovations.